Review of the Evidence from Epidemiology, Toxicology, and Lung Bioavailability on the Carcinogenicity of Inhaled Iron Oxide Particulates
Authors:
Open Access
- 24 February 2016
- journal article
- review article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 29 (3) , 237-254
Abstract
Since the iron-age and throughout the industrial age, humans have been exposed to iron oxides. Here, we review the evidence from epidemiology, toxicology and lung bioavailability as to whether iron oxides are likely to act as human lung carcinogens. Current evidence suggests that observed lung tumours in rat results from a generic particle overload effect and local inflammation that is rat-specific under the dosing conditions of intratracheal instillation. This mode of action therefore, is not relevant to human exposure. However, there are emerging differences seen in vitro, in cell uptake and cell bioavailability between ‘bulk’ iron oxides and ‘nano’ iron oxides. ‘Bulk’ particulates, as defined here, are those where greater than 70% are >100nm in diameter. Similarly, ‘nano’ iron oxides are defined in this context as particulates where the majority, usually >95% for pure engineered forms of primary particulates (not agglomerates), fall in the range 1-100nm in diameter. From the weight of scientific evidence, ‘bulk’ iron oxides are not genotoxic/mutagenic. Recent evidence for ‘nano’ iron oxide is conflicting regarding genotoxic potential, albeit genotoxicity was not observed in an in vivo acute oral dose study and ‘nano’ iron oxides are considered safe and are being investigated for biomedical uses; there is no specific in vivo genotoxicity study on nano iron oxides via inhalation. Some evidence is available that suggests, hypothetically due the larger surface area of ‘nano’ iron oxide particulates, toxicity could be exerted via the generation of reactive oxygen species (ROS) in the cell. However, the potential for ROS generation as a basis for explaining rodent tumourigenicity is only apparent if free iron from intracellular ‘nano’ scale iron oxide becomes bioavailable at significant levels inside the cell. This would not be expected from ‘bulk’ iron oxide particulates. Furthermore, human epidemiological evidence from a number of studies suggests that iron oxide is not a human carcinogen, and therefore based upon the complete weight of evidence, we conclude that ‘bulk’ iron oxides are not human carcinogens.Keywords
Funding Information
- REACH Consortium
This publication has 83 references indexed in Scilit:
- Contrasting macrophage activation by fine and ultrafine titanium dioxide particles is associated with different uptake mechanismsParticle and Fibre Toxicology, 2011
- Subchronic inhalation toxicity of iron oxide (magnetite, Fe3O4) in rats: pulmonary toxicity is determined by the particle kinetics typical of poorly soluble particlesJournal of Applied Toxicology, 2011
- Regulation of cellular iron metabolismBiochemical Journal, 2011
- Introduction to metallic nanoparticlesJournal of Pharmacy and Bioallied Sciences, 2010
- Soluble iron modulates iron oxide particle-induced inflammatory responses via prostaglandin E2 synthesis: In vitro and in vivo studiesParticle and Fibre Toxicology, 2009
- Shaping cups into phagosomes and macropinosomesNature Reviews Molecular Cell Biology, 2008
- Influence of particle dose on the cytotoxicity of hamster and rat pulmonary alveolar macrophage in vitroJournal of Toxicology and Environmental Health, 1994
- Long-term Carcinogenicity Bioassays on Industrial Chemicals and Man-made Mineral Fibers, at the Bentivoglio (BT) Laboratories of the Bologna Institute of Oncology: Premises, Programs, and ResultsToxicology and Industrial Health, 1991
- Carcinogenesis studies with iron oxidesExperimental pathology, 1991
- Carcinogenicity studies on fibres, metal compounds, and some other dusts in ratsExperimental pathology, 1987